etanercept and adalimumab) may vary and depend on the type of inflammatory disease. Potential immune mechanisms are: downmodulation of cytokine production and expression of adhesion molecules ...

The lower price for members is due to a new Pharmacy Care Reimagined model that unbundles the traditional PBM model, company ...

Blue Shield of California struck an unusual deal to buy a lower-cost version of Humira directly from a manufacturer, bypassing the giant pharmacy benefit managers that normally determine which ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira ... than others to take drastic action to lower drug costs, recently ...

Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per ...

AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira. CVS’s action led to a swift shift, with more patients transitioning to ...

UnitedHealth Group's Optum Rx will join its peers in the big three pharmacy benefit managers by pulling Humira from some of its preferred formularies, according to a report from Reuters.

TNF-α is a potent inducer of the inflammatory response, a key regulator of innate immunity and plays an important role in the regulation of Th1 immune responses against intracellular bacteria and ...

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the ...

Price Action: ABBV stock is down 0.45% at $195.93 at the last check on Thursday. Read Next: Amazon’s Profitable Essential Merchandise, Efficiency Gains Set To Drive Growth: Analyst ...